Advertisement

Clinical Drug Investigation

, Volume 34, Issue 5, pp 361–366 | Cite as

Immediate Neurological Recovery Following Perispinal Etanercept Years After Brain Injury

  • Edward TobinickEmail author
  • Helen Rodriguez-Romanacce
  • Arthur Levine
  • Tracey A. Ignatowski
  • Robert N. Spengler
Case Report

Abstract

Positron emission tomographic brain imaging and pathological examination have revealed that a chronic, intracerebral neuroinflammatory response lasting for years after a single brain injury may occur in humans. Evidence suggests the immune signaling molecule, tumor necrosis factor (TNF), is centrally involved in this pathology through its modulation of microglial activation, role in synaptic dysfunction, and induction of depressive symptoms and neuropathic pain. Etanercept is a recombinant TNF receptor fusion protein and potent TNF inhibitor that has been found to reduce microglial activation and neuropathic pain in multiple experimental models. We report that a single dose of perispinal etanercept produced an immediate, profound, and sustained improvement in expressive aphasia, speech apraxia, and left hemiparesis in a patient with chronic, intractable, debilitating neurological dysfunction present for more than 3 years after acute brain injury. These results indicate that acute brain injury-induced pathologic levels of TNF may provide a therapeutic target that can be addressed years after injury. Perispinal administration of etanercept is capable of producing immediate relief from brain injury-mediated neurological dysfunction.

Keywords

Traumatic Brain Injury Neuropathic Pain Etanercept Tumor Necrosis Factor Inhibitor Apraxia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

Dr. Edward Tobinick has multiple issued and pending US and foreign patents, assigned to TACT IP LLC, which claim methods of use of etanercept for the treatment of neurological disorders, including, but not limited to, US patents 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, and 8349323, all assigned to TACT IP LLC; and Australian patent 758523. Dr. Tobinick is the founder of the Institute of Neurological Recovery, a group of medical practices that utilize perispinal etanercept as a therapeutic modality, and also train physicians; he is also the Chief Executive Officer of TACT IP LLC. Helen Rodriguez-Romanacce and Arthur Levine are employees of the Institute of Neurological Recovery, Boca Raton, FL, USA. The professional activities of Tracey Ignatowski and Robert Spengler include their work as co-directors of neuroscience at NanoAxis, LLC, a company formed to foster the commercial development of products and applications in the field of nanomedicine, which include novel methods of inhibiting TNF.

Supplementary material

40261_2014_186_MOESM1_ESM.docx (283 kb)
Supplementary material 1 (DOCX 283 kb)

Supplementary material 2 (MPG 56592 kb)

References

  1. 1.
    Pappata S, Levasseur M, Gunn RN, Myers R, Crouzel C, Syrota A, et al. Thalamic microglial activation in ischemic stroke detected in vivo by PET and [11C]PK1195. Neurology. 2000;55(7):1052–4.PubMedCrossRefGoogle Scholar
  2. 2.
    Gentleman SM, Leclercq PD, Moyes L, Graham DI, Smith C, Griffin WS, et al. Long-term intracerebral inflammatory response after traumatic brain injury. Forensic Sci Int. 2004;146(2–3):97–104.PubMedCrossRefGoogle Scholar
  3. 3.
    Gerhard A, Schwarz J, Myers R, Wise R, Banati RB. Evolution of microglial activation in patients after ischemic stroke: a [11C](R)-PK11195 PET study. Neuroimage. 2005;24(2):591–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Folkersma H, Boellaard R, Yaqub M, Kloet RW, Windhorst AD, Lammertsma AA, et al. Widespread and prolonged increase in (R)-(11)C-PK11195 binding after traumatic brain injury. J Nucl Med Off Publ Soc Nucl Med. 2011;52(8):1235–9.Google Scholar
  5. 5.
    Ramlackhansingh AF, Brooks DJ, Greenwood RJ, Bose SK, Turkheimer FE, Kinnunen KM, et al. Inflammation after trauma: microglial activation and traumatic brain injury. Ann Neurol. 2011;70(3):374–83.PubMedCrossRefGoogle Scholar
  6. 6.
    Johnson VE, Stewart JE, Begbie FD, Trojanowski JQ, Smith DH, Stewart W. Inflammation and white matter degeneration persist for years after a single traumatic brain injury. Brain. 2013;136(Pt 1):28–42.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Tobinick E. Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases. CNS Drugs. 2011;25(2):145–55.PubMedCrossRefGoogle Scholar
  8. 8.
    Tobinick E, Kim NM, Reyzin G, Rodriguez-Romanacce H, Depuy V. Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept. CNS Drugs. 2012;26(12):1051–70.PubMedCrossRefGoogle Scholar
  9. 9.
    Sommer C, Schafers M, Marziniak M, Toyka KV. Etanercept reduces hyperalgesia in experimental painful neuropathy. J Peripher Nerv Syst. 2001;6(2):67–72.PubMedCrossRefGoogle Scholar
  10. 10.
    Chio CC, Lin JW, Chang MW, Wang CC, Kuo JR, Yang CZ, et al. Therapeutic evaluation of etanercept in a model of traumatic brain injury. J Neurochem. 2010;115(4):921–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Roh M, Zhang Y, Murakami Y, Thanos A, Lee SC, Vavvas DG, et al. Etanercept, a widely used inhibitor of tumor necrosis factor-alpha (TNF-alpha), prevents retinal ganglion cell loss in a rat model of glaucoma. PLoS One. 2012;7(7):e40065.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Patterson J. F-A-S test. In: Kreutzer JS, DeLuca J, Caplan B, editors. Encyclopedia of clinical neuropsychology. New York: Springer Science + Business Media; 2011. p. 1024.CrossRefGoogle Scholar
  13. 13.
    Gagnon C, Mathieu J, Desrosiers J. Standardized finger-nose test validity for coordination assessment in an ataxic disorder. Can J Neurol Sci Le J Can Sci Neurol. 2004;31(4):484–9.Google Scholar
  14. 14.
    Lanzino DJ, Conner MN, Goodman KA, Kremer KH, Petkus MT, Hollman JH. Values for timed limb coordination tests in a sample of healthy older adults. Age Ageing. 2012;41(6):803–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Numasawa T, Ono A, Wada K, Yamasaki Y, Yokoyama T, Aburakawa S, et al. Simple foot tapping test as a quantitative objective assessment of cervical myelopathy. Spine. 2012;37(2):108–13.PubMedCrossRefGoogle Scholar
  16. 16.
    Ross TP, Calhoun E, Cox T, Wenner C, Kono W, Pleasant M. The reliability and validity of qualitative scores for the Controlled Oral Word Association Test. Arch Clin Neuropsychol Off J Natl Acad Neuropsychol. 2007;22(4):475–88.CrossRefGoogle Scholar
  17. 17.
    Harkonen R, Harju R, Alaranta H. Accuracy of the Jamar dynamometer. J Hand Ther Off J Am Soc Hand Ther. 1993;6(4):259–62.CrossRefGoogle Scholar
  18. 18.
    Longwell T, Truax P. The differential effects of weekly, monthly, and bimonthly administration of the beck depression inventory-II: psychometric properties and clinical implications. Behav Ther. 2005;36:265–75.CrossRefGoogle Scholar
  19. 19.
    King NS, Crawford S, Wenden FJ, Moss NE, Wade DT. The Rivermead Post Concussion Symptoms Questionnaire: a measure of symptoms commonly experienced after head injury and its reliability. J Neurol. 1995;242(9):587–92.PubMedCrossRefGoogle Scholar
  20. 20.
    De Simoni MG, Perego C, Ravizza T, Moneta D, Conti M, Marchesi F, et al. Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus. Eur J Neurosci. 2000;12(7):2623–33.PubMedCrossRefGoogle Scholar
  21. 21.
    Vezzani A. Epilepsy and inflammation in the brain: overview and pathophysiology. Epilepsy Currents. 2014;14(1 Suppl):3–7.CrossRefGoogle Scholar
  22. 22.
    Vezzani A, French J, Bartfai T, Baram TZ. The role of inflammation in epilepsy. Nat Rev Neurol. 2011;7(1):31–40.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Jankowsky JL, Patterson PH. The role of cytokines and growth factors in seizures and their sequelae. Prog Neurobiol. 2001;63(2):125–49.PubMedCrossRefGoogle Scholar
  24. 24.
    Plata-Salaman CR, Ilyin SE, Turrin NP, Gayle D, Flynn MC, Romanovitch AE, et al. Kindling modulates the IL-1beta system, TNF-alpha, TGF-beta1, and neuropeptide mRNAs in specific brain regions. Brain Res Mol Brain Res. 2000;75(2):248–58.PubMedCrossRefGoogle Scholar
  25. 25.
    Turrin NP, Rivest S. Innate immune reaction in response to seizures: implications for the neuropathology associated with epilepsy. Neurobiol Dis. 2004;16(2):321–34.PubMedCrossRefGoogle Scholar
  26. 26.
    Mraovitch S, Calando Y, Regnier A, Lamproglou I, Vicaut E. Post-seizures amygdaloallocortical microvascular lesion leading to atrophy and memory impairment. Neurobiol Dis. 2005;19(3):479–89.PubMedCrossRefGoogle Scholar
  27. 27.
    Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration. J Neuroinflam. 2008;5:2.CrossRefGoogle Scholar
  28. 28.
    Tobinick EL, Gross H. Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer’s disease. BMC Neurol. 2008;8:27.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Tobinick E. Perispinal etanercept for neuroinflammatory disorders. Drug Discov Today. 2009;14(3–4):168–77.PubMedCrossRefGoogle Scholar
  30. 30.
    Tobinick E. Tumour necrosis factor modulation for treatment of Alzheimer’s disease: rationale and current evidence. CNS Drugs. 2009;23(9):713–25.PubMedCrossRefGoogle Scholar
  31. 31.
    Tobinick E. Perispinal etanercept: a new therapeutic paradigm in neurology. Expert Rev Neurother. 2010;10(6):985–1002.PubMedCrossRefGoogle Scholar
  32. 32.
    Tobinick E. Deciphering the physiology underlying the rapid clinical effects of perispinal etanercept in Alzheimer’s disease. Curr Alzheimer Res. 2012;9(1):99–109.PubMedCrossRefGoogle Scholar
  33. 33.
    Tobinick E. The cerebrospinal venous system: anatomy, physiology, and clinical implications. Med Gen Med. 2006;8(1):53.CrossRefGoogle Scholar
  34. 34.
    Nathoo N, Caris EC, Wiener JA, Mendel E. History of the vertebral venous plexus and the significant contributions of Breschet and Batson. Neurosurgery. 2011;69(5):1007–14 (discussion 14).PubMedGoogle Scholar
  35. 35.
    Vox F, Capron AM, Kraus MF, Alexander GC, Kirschner KL. Balancing burdens and benefits: ethical issues of off-label prescription pharmaceutical use. PM R J Inj Funct Rehabil. 2013;5(10):882–9.CrossRefGoogle Scholar
  36. 36.
    Kerensky TA, Gottlieb AB, Yaniv S, Au SC. Etanercept: efficacy and safety for approved indications. Expert Opin Drug Saf. 2012;11(1):121–39.PubMedCrossRefGoogle Scholar
  37. 37.
    Furst DE, Fleischman R, Kalden J, Kavanaugh A, Sieper J, Mease P, et al. Documentation of off-label use of biologics in rheumatoid arthritis. Ann Rheum Dis. 2013;72(Suppl 2):ii35–51.PubMedGoogle Scholar
  38. 38.
    Beck JM, Azari ED. FDA, off-label use, and informed consent: debunking myths and misconceptions. Food Drug Law J. 1998;53(1):71–104.PubMedGoogle Scholar
  39. 39.
    Guidance for off-label use of drugs. Lancet Neurol. 2008;7(4):285.Google Scholar
  40. 40.
    Committee on Drugs. Policy statement: off-label use of drugs in children. Pediatrics. 2014;133:563–7.Google Scholar
  41. 41.
    Horrobin DF. Effective clinical innovation: an ethical imperative. Lancet. 2002;359(9320):1857–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn’t. BMJ. 1996;312(7023):71–2.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    American Psychiatric Association. The principles of medical ethics with annotations especially applicable to psychiatry. 2001st ed. Washington: American Psychiatric Association; 2001. p. 46.Google Scholar
  44. 44.
    Ghaemi SN, Goodwin FK. The ethics of clinical innovation in psychopharmacology: challenging traditional bioethics. Philos Ethics Humanit Med. 2007;2:26.PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Gray H, Holmes T. Anatomy, descriptive and surgical. 4th ed. London: Longmans, Green, and Co.; 1866.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Edward Tobinick
    • 1
    Email author
  • Helen Rodriguez-Romanacce
    • 1
  • Arthur Levine
    • 1
  • Tracey A. Ignatowski
    • 2
    • 3
  • Robert N. Spengler
    • 4
  1. 1.Institute of Neurological RecoveryBoca RatonUSA
  2. 2.Department of Pathology and Anatomical Sciences, School of Medicine and Biomedical Sciences, University at BuffaloThe State University of New YorkBuffaloUSA
  3. 3.Program for Neuroscience, School of Medicine and Biomedical Sciences, University at BuffaloThe State University of New YorkBuffaloUSA
  4. 4.BuffaloUSA

Personalised recommendations